CLINICAL TRIALS PROFILE FOR GLATOPA
✉ Email this page to a colleague
All Clinical Trials for GLATOPA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03982212 ↗ | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | Recruiting | University of Kansas Medical Center | Phase 1 | 2019-07-26 | The investigator believes that injecting Copaxone into tumors will help participants immune system fight cancer. This has been studied in mice and has shown encouraging results. Copaxone is a safe medication currently used to treat Multiple Sclerosis (MS) and has very few side effects. To be considered for this trial a tumor must be easy to be injected and must be at least the size of a pea. Participants will be closely monitored for any side effects. Tissue from before surgery will be compared to tissue after the treatment and surgery to be checked for immune response and anti-tumor effects. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLATOPA
Condition Name
Clinical Trial Locations for GLATOPA
Trials by Country
Clinical Trial Progress for GLATOPA
Clinical Trial Phase
Clinical Trial Sponsors for GLATOPA
Sponsor Name